Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
EDMONTON, Alberta, March 30, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) announced today that Tyler Robson, President of Cannabis, has left the Company in...
-
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel...
-
Record revenue of $119.9 million, up 21.1% YOY Record 426 boats sold in 2025, up 33% YOYIncreased 2026 revenue guidance to $150–$155 millionSuccessfully completed IPO, strengthening balance sheet and...
-
RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data...
-
Q4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting...
-
ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with...
-
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in EOS Energy Enterprises, Inc. (NASDAQ: EOSE) during the period November 5, 2025 through February 26, 2026 may...
-
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in Navan, Inc. (Nasdaq: NAVN) to contact the firm. WHO IS AFFECTED: Those who...
-
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- "Leading integrated security provider" with "strong year over year growth going forward." That was the promise. A stock that crashed 80% in a single day...
-
- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001) - Acoramidis mitigated the rise in NT-proBNP...